Posted On: January 09, 2015
Image Caption:
Dr. Mihailidis helped to develop and evaluated a smart wheelchair, which may increase the accessibility and safety of powered wheelchairs for older adults.
On December 15th, the federal government announced the creation of four new national research networks and the renewal of an existing network. One of these new networks—abbreviated as AGE-WELL—will be based at TRI and will be co-led by Dr. Alex Mihailidis (TRI Senior Scientist).
"AGE-WELL will use the world-class facilities at Toronto Rehab and Simon Fraser University and a strong research and industry partnership network across the country to establish Canada as a leader in designing and implementing technology that contributes significantly to the well-being of older people," said Dr. Mihailidis.
Dr. Pamela Ohashi (PM Cancer Centre Senior Scientist) will play an instrumental role in another newly established national research network—BioCanRX—devoted to the development of biological therapeutics for treating cancer. Biological therapeutics harness the power of antibodies, viruses and human cells to treat disease. Dr. Ohashi will co-lead the program focused on immune cell therapies.
Through the Networks of Centres of Excellence (NCE) program, the federal government has contributed $25 million to the five national research networks, in addition to the $35 million committed by the academic, public sector, not-for-profit and industry partners. The NCE program provides funding to help create networks—which bring together a critical mass of research, development and entrepreneurial expertise—and to focus these networks on strategic areas.
"AGE-WELL will use the world-class facilities at Toronto Rehab and Simon Fraser University and a strong research and industry partnership network across the country to establish Canada as a leader in designing and implementing technology that contributes significantly to the well-being of older people," said Dr. Mihailidis.
Dr. Pamela Ohashi (PM Cancer Centre Senior Scientist) will play an instrumental role in another newly established national research network—BioCanRX—devoted to the development of biological therapeutics for treating cancer. Biological therapeutics harness the power of antibodies, viruses and human cells to treat disease. Dr. Ohashi will co-lead the program focused on immune cell therapies.
Through the Networks of Centres of Excellence (NCE) program, the federal government has contributed $25 million to the five national research networks, in addition to the $35 million committed by the academic, public sector, not-for-profit and industry partners. The NCE program provides funding to help create networks—which bring together a critical mass of research, development and entrepreneurial expertise—and to focus these networks on strategic areas.
Comments